| Precision medicine: drowning in a regulatory soup? D Nicol, T Bubela, D Chalmers, J Charbonneau, C Critchley, J Dickinson, ... Journal of Law and the Biosciences 3 (2), 281-303, 2016 | 46 | 2016 |
| Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic D Nicol, L Eckstein, M Morrison, JS Sherkow, M Otlowski, T Whitton, ... Genome medicine 9, 1-4, 2017 | 26 | 2017 |
| Myriad's impact on gene patents M Aboy, K Liddell, J Liddicoat, C Crespo Nature biotechnology 34 (11), 1119-1123, 2016 | 24 | 2016 |
| International divergence in gene patenting D Nicol, RC Dreyfuss, ER Gold, W Li, J Liddicoat, G Van Overwalle Annual review of genomics and human genetics 20 (1), 519-541, 2019 | 19 | 2019 |
| How does emerging patent case law in the US and Europe affect precision medicine? M Aboy, K Liddell, C Crespo, IG Cohen, J Liddicoat, S Gerke, T Minssen Nature biotechnology 37 (10), 1118-1125, 2019 | 18 | 2019 |
| The examination effect: A comparison of the outcome of patent examination in the US, Europe and Australia AF Christie, C Dent, J Liddicoat J. Marshall Rev. Intell. Prop. L. 16, i, 2016 | 18 | 2016 |
| After Myriad, what makes a gene patent claim 'markedly different' from nature? M Aboy, J Liddicoat, K Liddell, M Jordan, C Crespo Nature Biotechnology 35 (9), 820-825, 2017 | 17 | 2017 |
| Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts? M Aboy, C Crespo, K Liddell, J Liddicoat, M Jordan Nature Biotechnology 36 (12), 1146-1149, 2018 | 16 | 2018 |
| A role for virtual biotechnology companies in drug discovery and development? D Nicol, J Liddicoat, C Critchley | 14 | 2013 |
| Mayo’s impact on patent applications related to biotechnology, diagnostics and personalized medicine M Aboy, C Crespo, K Liddell, T Minssen, J Liddicoat Nature Biotechnology 37 (5), 513-518, 2019 | 13 | 2019 |
| Are the gene-patent storm clouds dissipating? A global snapshot J Liddicoat, T Whitton, D Nicol Nature Biotechnology 33 (4), 347-352, 2015 | 13 | 2015 |
| European patent protection for medical uses of known products and drug repurposing M Aboy, K Liddell, M Jordan, C Crespo, J Liddicoat Nature Biotechnology 40 (4), 465-471, 2022 | 12 | 2022 |
| Continental drift? Do European clinical genetic testing laboratories have a patent problem? J Liddicoat, K Liddell, AH McCarthy, S Hogarth, M Aboy, D Nicol, S Patton, ... European Journal of Human Genetics 27 (7), 997-1007, 2019 | 11 | 2019 |
| The Effects of Myriad and Mayo on Molecular-Test Development in the United States and Europe: Interviews from the Frontline J Liddicoat, K Liddell, M Aboy Vand. J. Ent. & Tech. L. 22, 785, 2019 | 11 | 2019 |
| Repositioning Generic Drugs: Empirical Findings and Policy Implications J Liddicoat, K Liddell, J Darrow, M Aboy, M Jordan, C Crespo, T Minssen IIC-International Review of Intellectual Property and Competition Law 53 (9 …, 2022 | 10 | 2022 |
| Mapping the European patent landscape for medical uses of known products M Aboy, K Liddell, J Liddicoat, C Crespo, M Jordan Nature Biotechnology 39 (11), 1336-1343, 2021 | 9 | 2021 |
| Has the EU incentive for drug repositioning been effective? An empirical analysis of the “+ 1” regulatory exclusivity J Liddicoat, K Liddell, M Aboy, J Wested IIC-International Review of Intellectual Property and Competition Law 52 …, 2021 | 8 | 2021 |
| Provenance and risk in transfer of biological materials J Nielsen, T Bubela, DRC Chalmers, A Johns, L Kahl, J Kamens, ... PLoS Biology 16 (8), e2006031, 2018 | 7 | 2018 |
| Three dimensions of patent infringement: Liability for creation and distribution of CAD files J Liddicoat, JL Nielsen, D Nicol Australian Intellectual Property Journal, 2016 | 7 | 2016 |
| The innovation pool in biotechnology: the role of patents in facilitating innovation D Nicol, JL Nielsen, J Liddicoat, C Critchley, T Whitton Available at SSRN 2503314, 2014 | 6 | 2014 |
Dianne NicolProfessor of Law, University of TasmaniaAdresse e-mail validée de utas.edu.au
